DMDaniel Motola-Kuba

Daniel Motola-Kuba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Motola-Kuba has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico

    by María Yolanda Cervantes-Apolinar, Adriana Guzman-Holst, Abiel Mascareñas De Los Santos, Alejandro Ernesto Macías Hernández, Álvaro Cabrera, Argelia Lara-Solares, Carlos Abud Mendoza, Daniel Motola Kuba, Diana Fabiola Flores Díaz, Fernanda Salgado Gomez, et al.

    Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.


  • Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma

    by José Manuel Ruiz-Morales, Rita Dorantes-Heredia, Oscar Arrieta, Norberto C. Chávez-Tapia, Daniel Motola-Kuba

    Prognosis in patients with lung cancer is poor. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) are proteins involved in the invasion and metastases of cancer. The objective of this study is to determine if there is a relationship between tumor expression of NGAL and MMP-9 in lung adenocarcinoma patients with prognosis and overall survival. Retrospective analysis was made of patients with lung adenocarcinoma treated at Medica Sur Hospital between 2005 and 2013. Tumor tissue was analyzed for NGAL and MMP-9 expression by immunohistochemistry. We identified 41 patients. Mean overexpression in tumoral tissue of NGAL was 70 % and 30 % for MMP-9. Univariate analysis revealed that prognostic factors associated with overall survival (OS) were NGAL expression and stage at diagnosis. Median OS for NGAL expression P P = 0.002). No differences in OS were found for expression of MMP-9. Multivariate analysis revealed significance for OS in NGAL expression (HR 5.01 [95 % CI; 1.68–14.93] P = 0.004) and stage at diagnosis (HR 2.05 [95 % CI 1.30–3.22] P = 0.002). Tumoral tissue expression of NGAL ≥70 % confers a worse prognosis compared to those who did not. NGAL is an independent prognostic factor of stage at diagnosis.


  • Open Access

    Bone metastases as the initial presentation of hepatocellular carcinoma. Two case reports and a literature review

    by Jose M. Ruiz-Morales, Rita Dorantes-Heredia, Fredy Chable-Montero, Sara Vazquez-Manjarrez, Nahum Méndez-Sánchez, Daniel Motola-Kuba


  • Open Access

    Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy

    by Karla Sánchez-Lara, Ricardo Sosa-Sánchez, Dan Green-Renner, Cindy Rodríguez, Alessandro Laviano, Daniel Motola-Kuba, Oscar Arrieta

    To determine the relationship between energy and nutrient consumption with chemosensory changes in cancer patients under chemotherapy. We carried out a cross-sectional study, enrolling 60 subjects. Cases were defined as patients with cancer diagnosis after their second chemotherapy cycle (n = 30), and controls were subjects without cancer (n = 30). Subjective changes of taste during treatment were assessed. Food consumption habits were obtained with a food frequency questionnaire validated for Mexican population. Five different concentrations of three basic flavors --sweet (sucrose), bitter (urea), and a novel basic taste, umami (sodium glutamate)-- were used to measure detection thresholds and recognition thresholds (RT). We determine differences between energy and nutrient consumption in cases and controls and their association with taste DT and RT. No demographic differences were found between groups. Cases showed higher sweet DT (6.4 vs. 4.4 micromol/ml; p = 0.03) and a higher bitter RT (100 vs. 95 micromol/ml; p = 0.04) than controls. Cases with sweet DT above the median showed significant lower daily energy (2,043 vs.1,586 kcal; p = 0.02), proteins (81.4 vs. 54 g/day; p = 0.01), carbohydrates (246 vs.192 g/day; p = 0.05), and zinc consumption (19 vs.11 mg/day; p = 0.01) compared to cases without sweet DT alteration. Cases with sweet DT and RT above median were associated with lower completion of energy requirements and consequent weight loss. There was no association between flavors DT or RT and nutrient ingestion in the control group. Changes of sweet DT and bitter RT in cancer patients under chemotherapy treatment were associated with lower energy and nutrient ingestion. Taste detection and recognition thresholds disorders could be important factors in malnutrition development on patients with cancer under chemotherapy treatment.